CASE QA0279 NP

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Laurelee A. Duncan

Type or print name

Signature

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

DHAR ET AL.

APPLICATION NO: 10/681,924

FILED: OCTOBER 9, 2003

FOR: HEXAHYDRO-BENZIMIDAZOLONE COMPOUNDS USEFUL AS

ANTI-INFLAMMATORY AGENTS

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were first cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Attorney for Applicants

Reg. No. 44,096

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 609-252-5323

Date:

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# **INFORMATION DISCLOSURE CITATION**

(se several sheets if necessary)

ATTY. DOCKET NO. QA0279 NP APPLICATION NO. 10/681,924 APPLICANT DHAR ET AL. FILING DATE OCTOBER 9, 2003

Group

JUL 1 4 2004 BY

#### **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
-	AA	6,350,763	2/26/02	Kelly et al.			
	AB		·				
•	AC						
	AD						
	AE						
	AF						
	AG	·		·			
	АН	,					
	Al						
	AJ						
٠.	AK						
	AL						

### **FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
АМ	WO 98/39303	9/11/98	PCT				
AN	WO 99/11258	3/11/99	PCT		-		
AO	WO 99/20617	4/29/99	PCT	-			
 AP	WO 99/20618	4/29/99	PCT				
AQ	WO 99/49856	10/7/99	PCT				

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Anderson, D.C. et al., "Leukocyte LFA-1, OKM1, p150,95 deficiency syndrome: functional and biosynthetic studies of three kindreds", Federation Proc., Vol. 44, No. 10, pp. 2671-2677 (1985)
AS	Diamond, M.S. et al., "The dynamic regulation of integrin adhesiveness", Current Biology, Vol. 4, No. 6, pp. 506-517 (1994)
АТ	Górski, A., "The role of cell adhesion molecules in immunopathology", Immunology Today, Vol. 15, No. 6, pp. 251-255 (1994)

**EXAMINER** 

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. QA0279 NP APPLICATION NO. 10/681,924 APPLICANT DHAR ET AL. FILING DATE OCTOBER 9, 2003

Group

### **FOREIGN PATENT DOCUMENTS**

·		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRAN YES	SLATION NO
	2AA	WO 00/21920	4/20/00	PCT				
	2AB	WO 00/39081	7/6/00	PCT	<u> </u>			
•	2AC	WO 00/48989	8/24/00	PCT				
	2AD	WO 00/59880	10/12/00	PCT		,		
•	2AE	WO 01/06984	2/1/01	PCT				
	2AF	WO 01/07044	2/1/01	PCT				
	2AG	WO 01/07048	2/1/01	PCT		,		
	2AH	WO 01/07052	2/1/01	PCT				
	2AI	WO 01/07440	2/1/01	PCT				
	2AJ	WO 01/30781	5/3/01	PCT				
	2AK	WO 01/51508	7/19/01	PCT				
	2AL	WO 01/58853	8/16/01	PCT				
	2AM	WO 02/02522	1/10/02	PCT				
	2AN	WO 02/02539	1/10/02	PCT				
	2AO	WO 02/28832	4/11/02	PCT		٩		
	2AP	WO 02/42294	5/30/02	PCT				
	2AQ	WO 02/44181	6/6/02	PCT				
	2AR	WO 02/059114	8/1/02	PCT				
	AS							
	AT							
	AU							
	AV							
	AW							
	AX							
	AY							
	AZ							
EXAM	INER			DATE CONSIDERED	-			

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.